We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Alzheimer’s patients who took dipeptidyl peptidase-4 inhibitors (DPP-4i) for type 1 diabetes had lower levels of brain amyloid beta than both diabetic patients who hadn’t taken the drug, and a control group of amyloid-positive nondiabetic patients. Read More
Expanding its existing Solidarity trial, the World Health Organization (WHO) will test three additional anti-inflammatory drugs as potential treatments for COVID-19. Read More
AstraZeneca (AZ) and Daiichi Sankyo have announced that an interim analysis from a phase 3 trial showed that their antibody-drug conjugate Enhertu (trastuzumab deruxtecan) posted positive progression-free survival relative to trastuzumab emtansine (T-DM1). Read More
A multidrug chemotherapy cocktail featuring Polivy (polatuzumab vedotin) has scored high as a first-line therapy for patients with diffuse large B-cell lymphoma, (DLBCL), according to preliminary information released by Roche subsidiary Genentech. Read More
In a study of 100 patients who were randomized to receive Nexviazyme or another FDA-approved enzyme replacement therapy, the two treatments showed similar efficacy in improving lung function. Read More
Mechanically ventilated patients with COVID-19 were 44 percent less likely to die when Olumiant (baricitinib) was added to the standard treatment regimen, according to a substudy of Eli Lilly’s COV-BARRIER trial. Read More